Better Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02 2022 - 4:01PM
Business Wire
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital
therapeutics company developing a novel form of cognitive
behavioral therapy to address the root causes of cardiometabolic
diseases, today announced that the compensation committee of Better
Therapeutics’ board of directors approved the grant of a
nonqualified stock option exercisable for 200,000 shares of Better
Therapeutics’ common stock to Diane Gomez-Thinnes, Chief Commercial
Officer, under the company’s 2022 Inducement Plan, effective on
December 1, 2022 (Grant Date). The stock option was granted as an
inducement material to Ms. Gomez-Thinnes becoming an employee of
Better Therapeutics in accordance with Nasdaq Listing Rule
5635(c)(4).
The stock option will have a per share exercise price equal to
the closing price of a share of Better Therapeutics’ common stock
on the Grant Date. The stock option vests in equal annual
installments over a four-year period starting on the one-year
anniversary of the Grant Date, subject to Ms. Gomez-Thinnes’
continued service through the applicable vesting dates. The stock
option is subject to the terms and conditions of the company’s 2022
Inducement Plan and applicable stock option agreement
thereunder.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy
(CBT) to address the root causes of cardiometabolic diseases. The
company has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The CBT delivered by Better
Therapeutics’ PDT is designed to enable changes in neural pathways
of the brain so lasting changes in behavior become possible.
Addressing the underlying causes of these diseases has the
potential to dramatically improve patient health while lowering
healthcare costs. Better Therapeutics’ clinically validated mobile
applications, if authorized for marketing, are intended to be
prescribed by physicians and reimbursed like traditional
medicines.
For more information visit: bettertx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221202005413/en/
Investor Relations: Mark Heinen IR@bettertx.com
Media: Ryan McKenna at Real Chemistry
rmckenna@realchemistry.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Sep 2023 to Sep 2024